8-K current report · filed Nov 5, 2026

Akebia Therapeutics, Inc. (AKBA) 8-K Current Report: November 5, 2026

Item 2.02Item EX-99.1AKBA overview

Short answer

Akebia Therapeutics, Inc. (AKBA) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Third-quarter results for period ended September 30, 2026 announced.

Akebia Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Third-quarter results for period ended September 30, 2026 announced
  • Recent business highlights included alongside financial results
  • Investor-relevant figures and management commentary available in Exhibit 99.1 press release

Item EX-99.1 · Exhibit EX-99.1

  • Q3 revenue $36.9M, down from $58.8M, driven by Auryxia revenue falling to $20.0M amid generic competition
  • Vafseo revenue $14.8M, while active patients reached approximately 11,500, up 140% year over year
  • Vafseo growth offset by customer inventory reduction and TDAPA expiration approaching, creating near-term revenue volatility
  • Net loss $14.4M versus $0.5M net income, despite SG&A falling to $23.5M from $29.1M
  • Cash $159.3M, down from $184.8M at December 31, with management targeting at least two years of funding and term-loan refinancing

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Akebia Therapeutics, Inc. 8-K filings

Get the next AKBA 8-K as it lands

Follow AKBA for push alerts, or ask the research agent what this filing means.